Neutralizing G-CSF prevents neutrophil accumulation and mitigates the T cell suppressive phenotype of neutrophils.743 A phase I clinical trial (NCT02718911) evaluated the safety, pharmacokinetics, and anti-tumor activity of LY3022855, a CSF1R inhibitor, in combination with durvalumab or tremelimumab for the treatment of advanced solid cancers.744 Additionally, blocking pathways involved in neutrophil recruitment has demonstrated potential for halting cancer progression. This evidence concerns the gene CSF3 and neoplasm.